Tags

Type your tag names separated by a space and hit enter

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Emerg Microbes Infect. 2021 Dec; 10(1):1241-1243.EM

Abstract

In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.

Authors+Show Affiliations

Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Pub Type(s)

Letter

Language

eng

PubMed ID

34092181

Citation

Zani, Alberto, et al. "Serosurvey in BNT162b2 Vaccine-elicited Neutralizing Antibodies Against Authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 Variants." Emerging Microbes & Infections, vol. 10, no. 1, 2021, pp. 1241-1243.
Zani A, Caccuri F, Messali S, et al. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Emerg Microbes Infect. 2021;10(1):1241-1243.
Zani, A., Caccuri, F., Messali, S., Bonfanti, C., & Caruso, A. (2021). Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Emerging Microbes & Infections, 10(1), 1241-1243. https://doi.org/10.1080/22221751.2021.1940305
Zani A, et al. Serosurvey in BNT162b2 Vaccine-elicited Neutralizing Antibodies Against Authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 Variants. Emerg Microbes Infect. 2021;10(1):1241-1243. PubMed PMID: 34092181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. AU - Zani,Alberto, AU - Caccuri,Francesca, AU - Messali,Serena, AU - Bonfanti,Carlo, AU - Caruso,Arnaldo, PY - 2021/6/8/pubmed PY - 2021/6/24/medline PY - 2021/6/7/entrez KW - BNT162b2 vaccine KW - SARS-CoV-2 KW - neutralizing antibodies KW - variant of concern KW - variant of interest SP - 1241 EP - 1243 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 10 IS - 1 N2 - In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/34092181/Serosurvey_in_BNT162b2_vaccine_elicited_neutralizing_antibodies_against_authentic_B_1_B_1_1_7_B_1_351_B_1_525_and_P_1_SARS_CoV_2_variants_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1940305 DB - PRIME DP - Unbound Medicine ER -